Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTONASDAQ:CRDFNASDAQ:LIFENASDAQ:TALS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.16-4.9%$1.57$1.15▼$8.70$18.24M1.2987,161 shs47,086 shsCRDFCardiff Oncology$3.99-4.5%$4.22$0.94▼$6.42$178.27M1.941.48 million shs586,485 shsLIFEaTyr Pharma$1.60-0.6%$1.82$1.08▼$2.70$108.36M1.25503,025 shs306,540 shsTALSTalaris Therapeutics$16.00+3.8%$18.84$0.89▼$27.95$684.22M2.18386,531 shs448,811 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences-0.81%-3.17%-19.21%-36.13%-83.06%CRDFCardiff Oncology+0.24%-7.11%-29.27%+180.54%+178.67%LIFEaTyr Pharma-1.23%+0.63%-16.67%+3.23%-21.95%TALSTalaris Therapeutics-2.65%-15.51%-38.83%-58.09%+478.16%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences2.6674 of 5 stars3.55.00.00.02.80.00.6CRDFCardiff Oncology0.5973 of 5 stars3.52.00.00.00.00.00.0LIFEaTyr Pharma2.8085 of 5 stars3.45.00.00.03.21.70.0TALSTalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences3.00Buy$19.801,606.90% UpsideCRDFCardiff Oncology3.00Buy$10.50163.16% UpsideLIFEaTyr Pharma2.75Moderate Buy$23.671,383.80% UpsideTALSTalaris TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest APTO, CRDF, LIFE, and TALS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$5.003/27/2024APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.003/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.003/6/2024CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $14.003/1/2024CRDFCardiff OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $7.002/21/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.002/1/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $5.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/ACRDFCardiff Oncology$490K363.82N/AN/A$1.56 per share2.56LIFEaTyr Pharma$350K309.61N/AN/A$1.54 per share1.04TALSTalaris TherapeuticsN/AN/AN/AN/A$4.33 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$7.72N/AN/AN/AN/A-458.70%-205.30%5/13/2024 (Estimated)CRDFCardiff Oncology-$41.44M-$0.93N/AN/AN/A-8,492.01%-50.13%-44.31%5/2/2024 (Estimated)LIFEaTyr Pharma-$50.39M-$0.96N/AN/AN/AN/A-49.84%-39.12%5/14/2024 (Estimated)TALSTalaris Therapeutics-$73.89M-$1.79N/A∞N/AN/A-39.93%-37.37%N/ALatest APTO, CRDF, LIFE, and TALS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023APTOAptose Biosciences-$1.48-$1.44+$0.04-$1.44N/AN/A3/14/2024Q4 2023LIFEaTyr Pharma-$0.23-$0.25-$0.02-$0.25N/AN/A2/29/2024Q4 2023CRDFCardiff Oncology-$0.26-$0.21+$0.05-$0.21$0.08 million$0.16 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/ATALSTalaris TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A0.780.78CRDFCardiff OncologyN/A7.417.41LIFEaTyr Pharma0.026.276.27TALSTalaris TherapeuticsN/A15.4115.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%CRDFCardiff Oncology16.29%LIFEaTyr Pharma61.72%TALSTalaris Therapeutics67.61%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences9.53%CRDFCardiff Oncology6.30%LIFEaTyr Pharma3.70%TALSTalaris Therapeutics16.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences3115.72 million14.22 millionNo DataCRDFCardiff Oncology3144.68 million41.86 millionOptionableLIFEaTyr Pharma5667.94 million65.43 millionOptionableTALSTalaris Therapeutics8442.76 million35.71 millionNot OptionableAPTO, CRDF, LIFE, and TALS HeadlinesSourceHeadlineLongitude Venture Partners III, L.P.'s Net Worthbenzinga.com - February 25 at 9:31 PMTalaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15msn.com - November 1 at 8:40 AMTalaris Thera (NASDAQ: TALS) stock to jump 1,000% then fall $15 - weird and complexdhakatribune.com - October 20 at 7:22 AMTalaris Therapeutics goes ex-dividend tomorrowmsn.com - October 19 at 3:47 PMTalaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Biofinanznachrichten.de - October 18 at 8:02 AMTalaris shareholders approve merger, 1-for-10 reverse stock splitmsn.com - October 17 at 10:28 PMTalaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Biofinance.yahoo.com - October 17 at 10:28 PMTalaris Therapeutics Inc [TALS] Insider Ildstad Suzanne sells 12,942 Shares – Insider Selling Alertknoxdaily.com - October 16 at 1:01 PMShares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to Mergermarketwatch.com - October 6 at 8:19 PMTalaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Biofinance.yahoo.com - October 6 at 8:19 PMNew York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeuticsfinance.yahoo.com - October 4 at 9:59 AMWe're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Ratefinance.yahoo.com - September 12 at 5:34 PMSHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – TALS,bakersfield.com - August 23 at 11:00 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOTmarkets.businessinsider.com - August 15 at 6:25 PMImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Businessfinance.yahoo.com - August 14 at 3:38 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURFmarkets.businessinsider.com - August 8 at 8:33 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALS, NETI, AMED, GHLbakersfield.com - July 29 at 5:47 PMMoore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firmbenzinga.com - July 28 at 4:44 PMSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)markets.businessinsider.com - July 27 at 11:10 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMSmarkets.businessinsider.com - July 18 at 1:26 PMTalaris Therapeutics: Cashing Out Ahead Of Tourmaline Mergermsn.com - July 18 at 8:26 AMDirector Ildstad Suzanne sale 12,942 shares of Talaris Therapeutics Inc. [TALS]knoxdaily.com - July 14 at 11:38 PMTalaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75msn.com - July 6 at 8:45 PMNews: Talaris Therapeutics Inc.’s Director Ildstad Suzanne reduceds 12,942 sharesknoxdaily.com - July 3 at 6:19 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksApril 25, 2024 2:14 AMView Stock market today: Wall Street falls on double dose of disappointing economic data, as Meta sinksFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeBlackstone’s $10 Billion Bet on Property Prices Going UpApril 11, 2024 7:30 AMView Blackstone’s $10 Billion Bet on Property Prices Going UpAll Headlines Company DescriptionsAptose BiosciencesNASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Cardiff OncologyNASDAQ:CRDFCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Talaris TherapeuticsNASDAQ:TALSTalaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.